New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Xenon Pharmaceuticals Inc.

Contributing Author

Recent Articles by Xenon Pharmaceuticals Inc.

Oct-07	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Sep-25	Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain XENE GlobeNewswire
Aug-29	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Aug-11	Xenon Reports Second Quarter 2025 Financial Results & Business Update XENE GlobeNewswire
Aug-04	Xenon to Report Q2 2025 Financial Results on August 11, 2025 XENE GlobeNewswire
Aug-01	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Jun-27	Xenon Joins the Russell 3000 and Russell 2000 Indexes XENE GlobeNewswire
Jun-26	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Jun-24	Xenon Announces Appointment of Darren Cline as Chief Commercial Officer XENE GlobeNewswire
Jun-03	Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference XENE GlobeNewswire
May-30	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
May-14	Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference XENE GlobeNewswire
May-12	Xenon Reports First Quarter 2025 Financial Results and Provides Business Update XENE GlobeNewswire
May-05	Xenon to Report Q1 2025 Financial Results on May 12, 2025 XENE GlobeNewswire
May-02	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.